- Design
- Assay development and validation with clinical cohort analysis
- Population
- 121 children with biopsy-confirmed MCD or primary FSGS, plus controls
- Primary outcome
- Agreement with IP-Western blot; association with disease activity and relapse
- Effect
- Concordance 86.8%, kappa 0.714; positive 41.3% vs 28.1% by reference method
A study in Kidney International (21 September) developed an automated chemiluminescence immunoassay for anti-nephrin IgG and tested it in 121 children with biopsy-confirmed minimal change disease (103) or primary FSGS (18), alongside disease and healthy controls. Results were compared with the research reference method, immunoprecipitation-Western blot.
Agreement was substantial (86.8% concordance, kappa 0.714), and the automated assay found more positives (41.3% vs 28.1%). Among children with nephrotic-range proteinuria, antibody positivity went with heavier proteinuria, lower albumin and steroid sensitivity. Higher antibody levels were associated with shorter relapse-free survival, and positivity during remission with relapse within three months.
Anti-nephrin antibodies are reshaping how minimal change disease and some FSGS are understood — as autoimmune podocytopathies. A standardised, automated test is what would let this reach routine practice, including as a monitoring tool. It is not yet available clinically in most centres, including in India.
- Recognise anti-nephrin-positive disease as an autoimmune podocytopathy
- Where testing is available, measure anti-nephrin IgG at presentation of nephrotic syndrome
- Consider repeat testing in remission as a possible relapse predictor, within research or specialist settings
- Do not use a negative result to exclude immune-mediated disease
Why it matters
A reliable routine test would let nephrologists stratify and monitor nephrotic syndrome by its cause rather than by histology alone.
Don't overread it
This is a single-centre paediatric validation study; the assay is not yet a validated clinical test.
The statistics, in plain English
A kappa of 0.71 indicates substantial agreement beyond chance. Detecting more positives could mean better sensitivity or more false positives; antigen-inhibition tests support true binding. The relapse associations come from one paediatric cohort.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for nephrology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free